Electronic Cigarettes in Youth with Asthma

项目名称：电子烟对青少年哮喘的影响 项目概要/摘要： 哮喘是美国最常见的儿科慢性疾病，影响超过600万儿童 和青少年。虽然众所周知，传统的“可燃”烟草是一种刺激物， 在哮喘急性发作时，人们对电子烟（EC）可能对呼吸系统的影响知之甚少。 青少年哮喘患者的健康状况。EC看起来和感觉像普通香烟，但不含烟草， 需要燃烧或产生烟雾。EC目前正在向成年吸烟者销售，作为替代品。 香烟越来越受欢迎。令人担忧的是，在过去两年中， 一些研究估计，15-19岁的青少年中有多达五分之一的人尝试过EC。 最近的数据表明，患有哮喘的年轻人比健康的同龄人更有可能使用EC。尽管 这些令人震惊的速度，EC吸收青年哮喘，很少有人了解这一点 现象目前的研究旨在确定为什么患有哮喘的青少年可能选择使用EC， 获得EC，以及他们如何看待EC的风险。首先，我们将描述使用模式， 社会人口学特征、使用和感知的哮喘青年中使用EC的危害 NIH/FDA烟草与健康人群评估（PATH）第1波研究数据。二是 使用定性技术来描述报告的EC知识，访问，使用和感知风险 在目前使用EC（过去7天）或从未使用EC的青少年哮喘患者中 6个焦点组（n = 60）。定性数据分析将调查与感知相关的主题 以及使用EC治疗青少年哮喘。最后，我们将评估EC使用与 呼吸系统健康的标志物，包括肺功能（FEV 1，FEV 1/FEVC）和炎症（呼出 一氧化氮; FeNO），在同一样本的60名青年哮喘谁是目前的EC用户或 从未使用者研究EC使用对呼吸/炎症生物标志物的潜在急性影响。 我们预期急性呼吸道生物标志物（即，FEV 1、FEV 1/FVC、FeNO）和 EC使用。这项创新研究将具有临床和

Project Title: Electronic Cigarettes in Youth with Asthma Project Summary/ Abstract: Asthma is the most common pediatric chronic illness in the United States, affecting over six million children and adolescents. While it is well established that traditional “combustible” tobacco is an irritant and can initiate asthma exacerbations, little is known about the impact electronic cigarettes (ECs) may have on respiratory health of adolescents with asthma. ECs can look and feel like regular cigarettes but do not contain tobacco, require combustion, or produce smoke. ECs are currently being marketed to adult smokers as an alternative to cigarettes and are increasing in popularity. Alarmingly, use of ECs has tripled over the last two years among adolescents, and some studies estimate that as many as 1 in 5 adolescents aged 15-19 have tried ECs. Recent data indicate that youth with asthma are more likely than their healthy peers to use ECs. Despite these alarming rates of EC uptake among youth with asthma, little is understood about this phenomenon. The current study seeks to identify why youth with asthma may choose to use ECs, how they obtain ECs, and how they perceive the risk of ECs. First, we will characterize patterns of use, sociodemographic characteristics, access, and perceived harm of ECs in youth with asthma using the NIH/FDA Population Assessment of Tobacco and Health (PATH) Wave 1 Study Data. Second, we will use qualitative techniques to characterize reported knowledge of ECs, access, use, and perceived risk among youth with asthma who are current EC users (past 7 days) or have never used ECs in a series of six focus groups (n = 60). Qualitative data analysis will investigate themes associated with perceptions and use of ECs for youth with asthma. Lastly, we will evaluate the association between EC use and markers of respiratory health, including lung function (FEV1, FEV1/FEVC), and inflammation (exhaled nitric oxide; FeNO), in the same sample of 60 youth with asthma who are either current EC users or never-users to investigate potential acute effects of EC use on respiratory/inflammatory biomarkers. We anticipate a negative association between acute respiratory biomarkers (i.e., FEV1, FEV1/FVC, FeNO) and EC use. This innovative study will have both clinical and